NEW YORK (GenomeWeb News) – Caris Life Sciences will offer Signal Genetics' gene expression profile test for multiple myeloma under an agreement announced today.
Caris will exclusively offer Signal's Myeloma Prognostic Risk Signature, or MyPRS, test to community-based hematologists and medical oncologists across the US through its Hematology Pathology Services. Signal Genetics' CLIA-certified laboratory in Little Rock, Ark., will analyze the test while Caris will incorporate test results into its summary reports.
Financial and other terms of the deal were not disclosed.
According to New York-based Signal, the MyPRS test offers "the most detailed expression profiling information for multiple myeloma patients available on the market." It analyzes and applies a proprietary algorithm to a defined number of relevant genes to determine a gene expression profile associated with a patient's condition. The profile "allows physicians to gain a predictive view of their patient's prognosis, enabling truly personalized treatment options," Signal said.